FirsthandHealth
medRxiv PreprintsInternational20 November 2026

Discovery and Cross-Omic Replication of a Candidate Plasma Proteomic Signature for Anti-TNF Response in Crohn's Disease

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background and Aims: Despite expanding therapeutic options for Crohn's disease (CD), treatment selection remains largely empiric. Identifying biomarkers linking inflammatory endotypes to treatment outcomes could inform first-line therapy selection. We sought to identify baseline plasma proteins associated with clinical, biochemical, and endoscopic outcomes in patients with CD receiving anti-TNF therapy. Methods: In this prospective multicenter cohort, children and young adults with CD initiating infliximab or adalimumab underwent plasma proteomic profiling at baseline and months 3 and 12 using
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.